Abbott Ups Its Ante On ADCs With Expanded Seattle Genetics Deal
This article was originally published in The Pink Sheet Daily
Abbott broadens its deal with Seattle Genetics in the hot space of antibody-drug conjugates just days after announcing a pipeline setback with another partner.
You may also be interested in...
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?